凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002821 凯莱英

开盘竞价 11-19 09:30:00

{"stockData":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":83.33,"timestamp":1731979398000,"preClose":82.89,"halted":0,"volume":0,"delay":0,"floatShares":329000000,"shares":368000000,"eps":2.0914,"marketStatus":"开盘竞价","marketStatusCode":1,"change":0.44,"latestTime":"11-19 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":83.33,"askSize":39,"bidPrice":83.33,"bidSize":39,"shortable":0,"etf":0,"ttmEps":2.0914,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"adjPreClose":82.89,"symbolType":"stock","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":91.18,"lowLimit":74.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":367718103,"pbRate":1.83,"roa":"--","roe":"3.98%","epsLYR":6.26,"committee":-0.025,"marketValue":30642000000,"floatMarketCap":27387000000,"peRate":39.844125,"changeRate":0.0053,"turnoverRate":0,"status":0},"requestUrl":"/m/hq/s/002821","defaultTab":"news","newsList":[{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"hk","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["NVO","BK0251","BK0070","BK0012","LU0405327148.USD","01801","BK4007","BK0028","BK0183","LU1328615791.USD","BK4585","BK0060","600276","BK0113","BK0201","BK0114","LU2148510915.USD","LU0154236417.USD","688076","BK0042","LU1093756168.USD","LU1064131003.USD","002821","300003","BK0132","BK0196","LU1093756325.SGD","603456","LU0405327494.USD","IE00BKVL7J92.USD","BK0239","LU2488822045.USD","LU1064130708.USD","300199","BK0077","IE00BZ1G4Q59.USD","BK0188","BK4532","BK4588","688117"],"gpt_icon":1},{"id":"2483328513","title":"凯莱英(06821)注销部分募集资金专户","url":"https://stock-news.laohu8.com/highlight/detail?id=2483328513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483328513?lang=zh_cn&edition=full","pubTime":"2024-11-15 18:20","pubTimestamp":1731666045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布公告，鉴于公司部分募投项目募集资金专户中存放的募集资金已按照规定用途使用完毕，为统筹资金账户管理，公司决定将开立于上海浦东发展银行股份有限公司天津分行、招商银行股份有限公司天津分行部分募集资金专户进行销户。截至本公告披露之日，公司已办理完毕上述募集资金专户的注销手续，并及时通知了保荐机构及保荐代表人，该募集资金专户相应的募集资金监管协议同时终止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","BK0239","BK0132","LU1328615791.USD","002821","BK1191"],"gpt_icon":0},{"id":"2483100790","title":"凯莱英：11月12日高管陈朝勇增持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483100790","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483100790?lang=zh_cn&edition=full","pubTime":"2024-11-13 21:01","pubTimestamp":1731502876,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月13日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年11月12日公司高管陈朝勇共增持公司股份5000.0股，占公司总股本为0.0014%。变动期间公司股价上涨1.61%，11月12日当日收盘报91.25元。凯莱英近半年内的董监高及核心技术人员增减持详情如下：凯莱英的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入809.29万，融资余额增加；融券净流出2800.0，融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300035304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","06821","002821","BK0239","BK1191","BK0132"],"gpt_icon":0},{"id":"2483101300","title":"凯莱英(06821)下跌5.49%，报58.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101300","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483101300?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:25","pubTimestamp":1731464727,"startTime":"0","endTime":"0","summary":"11月13日，凯莱英(06821)盘中下跌5.49%，截至10:25，报58.55元/股，成交396.47万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年三季报，凯莱英营业总收入40.91亿元、净利润7.1亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13102545231715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002821","LU1328615791.USD","BK0239","06821","BK1191","BK0132"],"gpt_icon":0},{"id":"2482901737","title":"凯莱英(06821)上涨5.47%，报63.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482901737","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482901737?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:50","pubTimestamp":1731376232,"startTime":"0","endTime":"0","summary":"11月12日，凯莱英(06821)盘中上涨5.47%，截至09:50，报63.6元/股，成交482.88万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年三季报，凯莱英营业总收入40.91亿元、净利润7.1亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/12095045179238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","002821","BK1191","LU1328615791.USD","06821","BK0132"],"gpt_icon":0},{"id":"2481775661","title":"凯莱英：11月7日高管陈朝勇增持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481775661","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481775661?lang=zh_cn&edition=full","pubTime":"2024-11-08 21:01","pubTimestamp":1731070870,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月8日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年11月7日公司高管陈朝勇共增持公司股份5000.0股，占公司总股本为0.0014%。变动期间公司股价上涨0.23%，11月7日当日收盘报88.5元。凯莱英近半年内的董监高及核心技术人员增减持详情如下：凯莱英的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出1438.07万，融资余额减少；融券净流出1600.0，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800040699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","BK1191","BK0132","BK0239","LU1328615791.USD","06821"],"gpt_icon":0},{"id":"2481973549","title":"财信证券：给予凯莱英买入评级，目标价位95.76元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481973549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481973549?lang=zh_cn&edition=full","pubTime":"2024-11-05 14:50","pubTimestamp":1730789429,"startTime":"0","endTime":"0","summary":"财信证券股份有限公司吴号近期对凯莱英进行研究并发布了研究报告《2024年三季报点评：小分子CDMO业务稳健增长，新兴业务有望改善》，本报告对凯莱英给出买入评级，认为其目标价位为95.76元，当前股价为87.0元，预期上涨幅度为10.07%。最新盈利预测明细如下：该股最近90天内共有16家机构给出评级，买入评级14家，增持评级2家；过去90天内机构目标均价为99.79。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500018906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002821","06821"],"gpt_icon":0},{"id":"2481751298","title":"凯莱英(06821)上涨5.12%，报59.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481751298","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481751298?lang=zh_cn&edition=full","pubTime":"2024-11-05 13:02","pubTimestamp":1730782950,"startTime":"0","endTime":"0","summary":"11月5日，凯莱英(06821)盘中上涨5.12%，截至13:02，报59.5元/股，成交1405.77万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年三季报，凯莱英营业总收入40.91亿元、净利润7.1亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/05130244934407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","002821","BK1191","LU1328615791.USD","06821","BK0132"],"gpt_icon":0},{"id":"2480883924","title":"凯莱英：10月31日高管陈朝勇增持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480883924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480883924?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:01","pubTimestamp":1730466068,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月1日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年10月31日公司高管陈朝勇共增持公司股份5000.0股，占公司总股本为0.0014%。变动期间公司股价下跌3.39%，10月31日当日收盘报82.91元。凯莱英近半年内的董监高及核心技术人员增减持详情如下：凯莱英的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出1.1亿，融资余额减少；融券净流入1200.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100045904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002821","06821","BK0132","LU1328615791.USD","BK1191"],"gpt_icon":0},{"id":"2480077155","title":"凯莱英(06821)截至10月末累计回购公司股份数量为1230.07万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480077155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480077155?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:57","pubTimestamp":1730455023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布公告，截至2024年10月31日，公司累计通过回购专用证券账户以集中竞价方式回购公司股份数量为1230.07万股，占公司A股总股本的3.5976%，最高成交价为102.00元/股，最低成交价为71.65元/股，合计支付的总金额为9.996亿元(不含交易费用)。本次回购股份符合公司回购方案及相关法律法规要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","BK1191","399300","BK0239","BK0132","LU1328615791.USD","159982","002821"],"gpt_icon":0},{"id":"2480074850","title":"凯莱英(002821.SZ)已累计回购3.5976%股份 耗资约10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480074850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480074850?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:17","pubTimestamp":1730452641,"startTime":"0","endTime":"0","summary":"智通财金APP讯，凯莱英(002821.SZ)发布公告，截至2024年10月31日，公司累计通过回购专用证券账户以集中竞价方式回购公司股份数量为1230.07万股，占公司A股总股本的3.5976%，最高成交价为102.00元/股，最低成交价为71.65元/股，合计支付的总金额为10亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","002821","LU1328615791.USD","06821","BK0132","BK0239"],"gpt_icon":0},{"id":"2480201645","title":"凯莱英（002821）10月31日主力资金净卖出2678.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480201645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480201645?lang=zh_cn&edition=full","pubTime":"2024-11-01 09:19","pubTimestamp":1730423979,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月31日收盘，凯莱英报收于82.91元，下跌3.39%，换手率1.57%，成交量5.17万手，成交额4.34亿元。近5日资金流向一览见下表：凯莱英融资融券信息显示，融资方面，当日融资买入4837.52万元，融资偿还3633.77万元，融资净买入1203.75万元。凯莱英主营业务：是一家全球领先、技术驱动型的医药外包服务一站式综合服务商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100010646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","BK0239","BK1191","BK0132","LU1328615791.USD","06821"],"gpt_icon":0},{"id":"2479959084","title":"凯莱英：10月30日高管陈朝勇增持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479959084","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479959084?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:01","pubTimestamp":1730379667,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月31日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年10月30日公司高管陈朝勇共增持公司股份5000.0股，占公司总股本为0.0014%。变动期间公司股价上涨1.85%，10月30日当日收盘报85.82元。凯莱英近半年内的董监高及核心技术人员增减持详情如下：凯莱英的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出1.22亿，融资余额减少；融券净流入600.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100043309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","002821","BK0132","LU1328615791.USD","06821","BK0239"],"gpt_icon":0},{"id":"2479772981","title":"港股异动 | 凯莱英(06821)跌近4% 三季度业绩改善初显 规模下滑导致费用端承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2479772981","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479772981?lang=zh_cn&edition=full","pubTime":"2024-10-31 14:43","pubTimestamp":1730357018,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英跌近4%，截至发稿，跌3.72%，报57港元，成交额938.23万港元。消息面上，凯莱英发布2024年第三季度业绩，该集团期内取得营业收入14.43亿元，同比减少18.09%；归属于上市公司股东的净利润2.11亿元，同比减少59.68%。前三季度，营业收入41.4亿元，同比减少35.14%；归属于上市公司股东的净利润7.1亿元，同比减少67.86%。国金证券指，剔除大订单后环比持续改善。另外，由于公司收入规模下滑，期内各项费用率均有所提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","06821","002821","BK0239","BK1191","BK0132"],"gpt_icon":0},{"id":"2479792858","title":"平安证券：给予凯莱英买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479792858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479792858?lang=zh_cn&edition=full","pubTime":"2024-10-31 08:27","pubTimestamp":1730334440,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,倪亦道近期对凯莱英进行研究并发布了研究报告《常规业务较快发展，毛利率有望触底回升》，本报告对凯莱英给出买入评级，当前股价为85.82元。　　维持“强烈推荐”评级。海外投融资环境逐步改善，叠加公司能力提升，获利能力有望持续改善，维持“强烈推荐”评级。最新盈利预测明细如下：该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均价为95.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100011879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","161027","002821"],"gpt_icon":0},{"id":"2479576663","title":"民生证券：给予凯莱英买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479576663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479576663?lang=zh_cn&edition=full","pubTime":"2024-10-31 04:56","pubTimestamp":1730321774,"startTime":"0","endTime":"0","summary":"民生证券股份有限公司王班,乔波耀近期对凯莱英进行研究并发布了研究报告《2024年三季报点评：毛利率持续改善，新签订单保持良好态势》，本报告对凯莱英给出买入评级，当前股价为85.82元。　　凯莱英　　事件：2024年10月30日，凯莱英发布2024年三季报业绩。最新盈利预测明细如下：该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均价为95.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100006310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","161027","06821"],"gpt_icon":0},{"id":"2479279876","title":"凯莱英：海通证券、汇添富基金等多家机构于10月30日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479279876?lang=zh_cn&edition=full","pubTime":"2024-10-30 18:05","pubTimestamp":1730282728,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月30日凯莱英发布公告称海通证券、汇添富基金、鹏华基金、嘉实基金、华宝基金、招商基金、富国基金、上海高毅资产、贝莱德基金、Goldman Sachs、Willing Capital、民生证券、3W Fund、Fidelity、Morgan Stanley、Springhill Fund、RBC Global、JP Morgan、HSBC、中信证券、国盛证券、浙商证券、平安证券、中信建投证券、兴业证券、中欧基金于2024年10月30日调研我司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000035817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","BK1564","06821","BK1147","BK0012","BK0132","BK0183","BK1191","06837","BK0239","LU1328615791.USD","BK0070","BK0028","BK0188","002821","600837"],"gpt_icon":0},{"id":"2479279310","title":"国金证券：给予凯莱英买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479279310?lang=zh_cn&edition=full","pubTime":"2024-10-30 18:02","pubTimestamp":1730282556,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维近期对凯莱英进行研究并发布了研究报告《三季度边际改善，看好公司底部反转》，本报告对凯莱英给出买入评级，当前股价为85.82元。报告期内，由于公司收入规模下滑，各项费用率均有所提升。截至报告期末多肽固相合成产能超过2万升。最新盈利预测明细如下：该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均价为95.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000035737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","002821"],"gpt_icon":0},{"id":"2479843281","title":"凯莱英前三季度净利7.1亿元，同比下降67.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479843281","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479843281?lang=zh_cn&edition=full","pubTime":"2024-10-29 22:05","pubTimestamp":1730210700,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 丁宁）10月29日晚间，凯莱英（002821）披露2024年三季报显示，公司前三季度实现营业收入41.4亿元，同比下降35.14%；归属净利润7.1亿元，同比下降67.86%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-10-29/doc-incufuvt7533970.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-10-29/doc-incufuvt7533970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002821","LU1328615791.USD","BK0132","BK1191","06821"],"gpt_icon":0},{"id":"2479403943","title":"凯莱英(002821.SZ)发布前三季度业绩，净利润7.1亿元，同比下降67.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479403943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479403943?lang=zh_cn&edition=full","pubTime":"2024-10-29 19:38","pubTimestamp":1730201895,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(002821.SZ)发布2024年三季度报告，前三季度，公司实现营业收入41.4亿元，同比下降35.14%。归属于上市公司股东的净利润7.1亿元，同比下降67.86%。归属于上市公司股东的扣除非经常性损益的净利润6.63亿元，同比下降67.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","002821"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-18","address":"天津市滨海新区经济技术开发区洞庭三街6号","stockEarnings":[{"period":"1week","weight":-0.0769},{"period":"1month","weight":0.0909},{"period":"3month","weight":0.2873},{"period":"6month","weight":0.0576},{"period":"1year","weight":-0.4143},{"period":"ytd","weight":-0.2665}],"companyName":"凯莱英医药集团(天津)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"36771万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　凯莱英医药集团(天津)股份有限公司是一家全球领先的服务于新药研发和生产的CDMO一站式综合服务商。为国内外大中型制药企业、生物技术公司提供高效和高质量的研发与生产服务，助推创新药的临床研究与商业化应用。主要包括临床阶段药品、商业化阶段药品、技术服务。公司是全球第五大创新药原料药CDMO公司，约占据1.5%的市场份额（第一名市场份额约为2.9%）；是中国最大的商业化阶段化学药物CDMO公司，约占据22%的市场份额。","serverTime":1731979404696,"listedPrice":30.53,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,002821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}